Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study).

X-ray computed follow-up studies melanoma positron emission tomography computed tomography prospective studies quality of life randomized controlled trial tomography

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 Feb 2022
Historique:
received: 19 01 2022
revised: 15 02 2022
accepted: 16 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

The benefit of imaging in the follow-up setting for high-risk melanoma patients is uncertain, and even less is known about the impact of intensive follow-up on the patient´s quality of life. In 2017, a Swedish prospective randomized multicenter study started, in which high-risk melanoma patients are randomly assigned 1:1 to follow-up by physical examinations +/- whole-body imaging. The first-year examinations are scheduled at 0, 6 and 12 months. The aim of this study was to investigate whether the patients´ health-related quality of life (HRQoL) and levels of anxiety and depression were affected at 1 year by imaging. Anxiety/depression and HRQoL were assessed at 0 and 12 months by the questionnaires Hospital Anxiety and Depression (HAD) scale and EORTC QLQ-C30 version 3. Expected baseline QLQ-C30 values for the patients were calculated using data from the general population. In total, 204 patients were analyzed. Mean differences in subscale scores at 1 year were not statistically significant either for HRQoL or for anxiety/depression. Baseline HRQoL did not differ from expected values in the general Swedish population. In conclusion, the patients in general coped well with the situation, and adding whole-body imaging to physical examinations did not affect the melanoma patients' HRQoL or levels of anxiety or depression.

Identifiants

pubmed: 35205786
pii: cancers14041040
doi: 10.3390/cancers14041040
pmc: PMC8869964
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond
ID : Not applicable
Organisme : Lion´s Cancer fund
ID : Not applicable

Références

J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
J Am Acad Dermatol. 2016 Sep;75(3):516-524
pubmed: 27183845
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Ann Oncol. 2018 Jul 1;29(7):1569-1574
pubmed: 29659679
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
BMC Cancer. 2020 Dec 7;20(1):1197
pubmed: 33287744
Eur J Surg Oncol. 2021 Dec;47(12):3020-3027
pubmed: 34120809
J Clin Oncol. 2018 Mar 1;36(7):667-673
pubmed: 28991513
JAMA. 1994 May 25;271(20):1587-92
pubmed: 8182811
J Surg Res. 2017 Jun 15;214:32-37
pubmed: 28624057
Ann Surg Oncol. 2019 Jun;26(6):1860-1868
pubmed: 30911946
Acta Oncol. 2000;39(4):477-84
pubmed: 11041109
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Plast Reconstr Surg. 2016 Aug;138(2):330e-340e
pubmed: 27465194
Eur J Cancer. 2012 Sep;48(13):2012-9
pubmed: 22196968

Auteurs

Ylva Naeser (Y)

Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Department of Oncology, Uppsala University Hospital, Entrance 101, First Level, 751 85 Uppsala, Sweden.

Hildur Helgadottir (H)

Department of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Theme Cancer, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Johan Hansson (J)

Theme Cancer, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Christian Ingvar (C)

Department of Surgery, Clinical Sciences, Lund University, BMC F12, 221 84 Lund, Sweden.

Nils O Elander (NO)

Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.

Petra Flygare (P)

Department of Oncology, Sundsvall County Hospital, Lasarettsgatan 21, 856 43 Sundsvall, Sweden.

Cecilia Nilsson (C)

Department of Oncology, Hospital of Västmanland Västerås, 721 89 Västerås, Sweden.

Frida Jakobsson (F)

Department of Oncology, Örebro University Hospital, 701 85 Örebro, Sweden.

Antonios Valachis (A)

Department of Oncology, Faculty of Medicine and Health, Örebro University, 701 82 Örebro, Sweden.

Dimitrios Papantoniou (D)

Department of Oncology, Ryhov County Hospital, 551 85 Jönköping, Sweden.

Agneta Nordin Danfors (A)

Department of Oncology, Visby County Hospital, St. Göransgatan 5, 621 84 Visby, Sweden.

Hemming Johansson (H)

Department of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Theme Cancer, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Anders Sundin (A)

Department of Surgical Sciences Radiology & Molecular Imaging, Uppsala University, 751 85 Uppsala, Sweden.

Yvonne Brandberg (Y)

Department of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.

Gustav J Ullenhag (GJ)

Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Department of Oncology, Uppsala University Hospital, Entrance 101, First Level, 751 85 Uppsala, Sweden.

Classifications MeSH